| Date | Title | Description | |
|---|---|---|---|
| 05 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted on 3 and 4 November | Download |
| 03 Nov 2021 | On business and financial situation | The Company releases the first nine months 2021 financial results presentation | Download |
| 03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 10 May 2018 | Otros sobre negocio y situación financiera | Update pivotal PRISMA-3 study of DORIA® (Risperidone ISM®) | Download |
| 25 Apr 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first quarter financial results | Download |
| 25 Apr 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI informs about the call for the 2018 Ordinary General Shareholders Meeting | Download |
| 25 Apr 2018 | Información sobre resultados | ROVI releases the 2018 first quarter results presentation | Download |
| 04 Apr 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2018 | Download |